

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number  
**WO 01/28538 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/00**

(21) International Application Number: **PCT/GB00/04017**

(22) International Filing Date: 18 October 2000 (18.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9924636.5 18 October 1999 (18.10.1999) GB

(71) Applicants (for all designated States except US):  
**NORGINE RESEARCH LIMITED** [GB/GB]; Mount  
Vernon Hospital, Rickmansworth Road, Northwood, Mid-  
dlesex HA6 2RN (GB). **PRESIDENT AND FELLOWS  
OF HARVARD COLLEGE** [US/US]; University Place,  
124 Mt. Auburn Street, Cambridge, MA 02138 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARRAS, Norman**  
[GB/GB]; Norgine Research Limited, Mount Vernon Hos-  
pital, Rickmansworth Road, Northwood, Middlesex HA6  
2RN (GB). **HECHTMAN, Herbert, B.** [US/US]; 3 Gle-  
noe Road, Chestnut Hill, MA 02167 (US).

(74) Agents: **ADAMS, Nicola et al.**; Abel & Imray, 20 Red  
Lion Street, London WC1R 4PQ (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished  
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **LAXATIVE PREPARATION**

(57) Abstract: The invention relates to L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof for use as a laxative, for treatment of constipation and for clearing the rectum and/or the colon of a mammal. Composition suitable for topical administration to an area of the gastrointestinal tract are provided. Orally administered preparations comprising for example an enteric coating that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system; or a combination thereof are also provided.

WO 01/28538 A2

## LAXATIVE PREPARATION

The present invention relates generally to laxatives.

5 Constipation is a widespread condition which generally gives rise to discomfort. The physical presence of faeces retained in the colon and/or the rectum gives rise to a feeling of malaise and headaches. In extreme cases of prolonged constipation dyschezia may result from the presence of  
10 scybala or faecaliths in the rectum. Dyschezia may also result from the inhibition of the defecation reflex in response to pain arising from haemorrhoids, ulceration of the anal mucosa or wounds (surgical or traumatic) of the anus.

15 Laxatives are agents that promote and assist defecation. There are four general types of laxatives that are currently available: 1) bulk-forming; 2) osmotic; 3) stimulatory; 4) softening agents. The present application is directed towards a new class of laxative.

20 With bulk laxatives, an increase in the volume of the contents of the colon stimulates local peristaltic activity and increases the strength of stimulation of the central reflexes concerned with defecation. Bulk laxatives simulate  
25 the effect of foods containing indigestible and non-absorbed constituents.

In contrast to bulk-forming laxatives, osmotic laxatives act to retain water in the colonic lumen thereby counteracting  
30 the normal dehydrating action of the colon. By suppressing the dehydration action of the colon, the osmotic laxative produces a faecal stream which is softer, bulkier and easier  
to expel.

Stimulatory laxatives increase peristalsis by stimulating the mucosa of the gut (probably by initiating local reflexes), the impulses arising in the mucosa and being transmitted through the intramural plexuses to the smooth muscle of the intestine. These agents can sometimes cause abdominal cramps; prolonged use can lead to deterioration of intestinal function, and can result in atonic colon.

Softening agents are generally surface-active compounds which act on the gastrointestinal tract in a manner similar to a detergent and produce softer faeces.

All of the methods so far mentioned vary in their speed of action, have a number of side effects and are not always effective. It is an objective of the present invention to provide a laxative that overcomes or ameliorates some or all of these problems.

Compositions comprising L-arginine are known to be effective in the treatment of haemorrhoids and haemorrhoidal pain (as described in WO96/32081). It has now been surprisingly found that formulations comprising L-arginine are effective as a laxative.

The invention provides laxative treatment of the mammalian, especially human, gastrointestinal (GI) tract using a preparation comprising the amino acid L-arginine, a derivative thereof, or pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier substance.

The invention provides a treatment for medical conditions of the gastrointestinal tract, including constipation. As used herein, the term "gastrointestinal tract" is defined as the part of the body which includes the oesophagus, stomach,

small and large intestines, and includes the colon, rectum and anus. The terms "topical" and "topical application" are defined as application of an active substance to surfaces of the body, and are used herein to mean application to an area  
5 of the gastrointestinal tract. This mode of administration is sometimes also known as "local" application. As used herein, the term "effective amount" refers to an amount of L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof that results in at least partial  
10 alleviation or mitigation of the medical condition. The terms "medicament", "composition" and "preparation" are used herein interchangeably.

The present invention provides the use of L-arginine, a  
15 derivative thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of constipation. The invention also provides the use of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament  
20 for use as a laxative, for example, in promoting and/or assisting defecation. The invention further provides the use of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for clearing the intestines, particularly the large  
25 intestine, especially the colon and/or rectum, in particular before a diagnostic, therapeutic or surgical procedure, especially a procedure to be carried out on the colon, rectum or anus, or elsewhere in the abdomen. The medicament is especially one that enables topical application of the L-  
30 arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof, that is to say, application to an area of the gastrointestinal tract.

The present invention also provides a method for the treatment of constipation in a mammal comprising applying an effective amount of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof to the

5 gastrointestinal tract of the mammal, especially to an area thereof. The invention also provides a method for promoting and/or assisting defecation in a mammal comprising applying an effective amount of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof to the

10 gastrointestinal tract of the mammal, especially to an area thereof. The invention further provides a method for clearing the intestines, particularly the large intestine, of a mammal, especially the colon and/or rectum, comprising applying an effective amount of L-arginine, a derivative

15 thereof, or a pharmaceutically acceptable salt thereof to the gastrointestinal tract of the mammal, especially to an area thereof, in particular before a diagnostic, therapeutic or surgical procedure, especially a procedure to be carried out on the colon, rectum or anus, or elsewhere in the abdomen.

20

In the above methods the mammal is especially a human, and in the uses according to the present invention, the recipient of the medicament is especially a human. The L-arginine, derivative thereof, or pharmaceutically acceptable salt

25 thereof is applied, in the form of a medicament, to the gastrointestinal tract, especially to an area thereof. That area is, for example, the gastrointestinal tract beyond the pyloric sphincter, for example, the gastrointestinal tract beyond the duodenum, for example, the gastrointestinal tract

30 beyond the ileum, for example, the colon and beyond, for example the rectum or anal canal. The area of the gastrointestinal tract to which the active substance is applied may be the colon and/or rectum.

The medicament comprising the L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof should be such that the active substance is applied to the desired site. The medicament is administered in an amount such that  
5 an effective amount of the L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof is administered to the desired site. The medicament generally comprises one or more pharmaceutically acceptable carriers.

10 The present invention is concerned with the treatment of constipation. Constipation may be acute, chronic or refractory and may be endogenous or exogenous. Exogenous constipation is caused by external agents. Opiate-induced constipation is a well-known example of exogenous  
15 constipation.

The invention is also concerned with the use of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof as a laxative, for example in promoting and/or  
20 assisting defecation. While laxatives are often used by those suffering from constipation, they may also be used to promote and/or assist defecation by subjects who do not have constipation as such but who should be prevented from straining at the stool, for example, patients suffering from  
25 hernia or cardiovascular disease. Laxatives may also be useful to patients with haemorrhoids and other anorectal disorders.

Clearing the large intestine, in particular the colon and/or  
30 rectum, also known as intestinal lavage, is important for diagnostic, therapeutic and surgical procedures on the colon, rectum or anus. It may also be desired to facilitate such procedures in other regions of the abdomen, for example, before examination, for example, radiological examination of



the kidneys or other abdominal or retroperitoneal structures. The term "colon and/or rectum" is used herein. However, it will be appreciated that an agent administered to the colon will generally also reach the rectum. Similarly, clearance  
5 of the colon will generally also result in clearance of the rectum. Conversely, application of an agent to the rectum or clearance of the rectum will not necessarily affect the colon.

- 10 Suitable pharmaceutically acceptable L-arginine salts for use according to the present invention include, for example, L-arginine monohydrochloride, L-arginine free base, L-arginine L-aspartate salt, L-glutamyl L-arginine, L-arginine hydrochloride, L-arginine hydroxamate, L-arginine phosphate,  
15 L-argininic acid, L-arginine benzylidene, L-arginine diflavinate, L-arginine dipicrate and L-arginine picrate. The hydrochloride salt is particularly preferred. Suitable derivatives of L-arginine include, for example, L-arginine methyl ester dihydrochloride, L-arginine agarose, L-arginine  
20 ethyl ester dihydrochloride, L-arginine-4-methoxy- $\beta$ -naphthylamide, L-arginine methyl ester p-toluenesulfonyl derivative, L-arginine- $\beta$ -naphthylamide hydrochloride, L-arginine-p-nitroanilide dihydrochloride, L-argininamide dihydrochloride, L-arginin-N<sup>G</sup>-amine (flavionate salt),  
25 argininosuccinic acid and L-argininamide. The term "pharmaceutically acceptable salts thereof" includes salts of L-arginine and salts of L-arginine derivatives. Generally the L-arginine derivative is preferably not a surfactant, for example not an acyl arginine surfactant, for example not N-  
30 -myristoyl-L-arginine methyl ester hydrochloride.

---

Preferably, L-arginine is used. A particularly suitable salt of L-arginine is L-arginine hydrochloride.

In one embodiment of the invention, the medicament is suitable for topical application via the anal canal, i.e. rectally. The carrier for the topical application can be any inert substance suitable for topical administration in the gastrointestinal tract, in particular for administration rectally to the colon and/or rectum, for example, a water-soluble jelly, for example, hydroxy methyl cellulose or a water-based gel, for example, as available from Johnson and Johnson under the name "K-Y Jelly"; a hydrogel; an anal suppository base or a cream.

In general, a carrier with a density higher than water, for example, a water based gel for example, as available from Johnson and Johnson under the name "K-Y Jelly" or a suppository base, is capable of subjecting an area to a prolonged exposure to the active ingredient.

Hydrogels may be selected that release the active substances at a pre-determined rate.

The amount of topical medicament administered is generally in the range of from 0.01 ml to 10 ml. The concentration of L-arginine in the topical medicament is generally in the range of from 0.1 mg to 800 mg per ml, preferably from 10 mg to 700 mg per ml, more preferably from 50 mg to 500 mg per ml, for example 400 mg per ml. The preferred amounts of L-arginine, or derivative or salt thereof, calculated as L-arginine, are accordingly from 0.1 to 7000 mg, more preferably from 0.5 to 5000 mg, for example, from 4 to 4000 mg.

Upon administration of the L-arginine, derivative thereof or pharmaceutically acceptable salt thereof in a suitable carrier to the rectum, anus or colon, defecation generally results and the symptoms of constipation are reduced. Hence

the use of L-arginine, derivatives thereof and salts thereof according to the present invention enables the clearance of faecal material retained in the lower gastrointestinal tract, for example the colon and/or rectum at the time of  
5 administration.

The invention may or may not rely on the delivery of the active substance to the rectum, anus or colon. The mechanism of action of the treatment is at present not known. It is  
10 possible that the mechanism involves NO release.

At least two types of NO synthase enzymes contribute to production of NO. An inducible NO synthase depends upon protein synthesis of the enzyme before NO production begins.  
15 A constitutive NO synthase enzyme is present in endothelial cells, platelets, brain, and smooth muscle cells. It is possible that L-arginine directly activates the constitutively expressed NO synthase enzyme to cause production of NO or a related compound, since defecation  
20 generally occurs very soon after application of this agonist. Following NO production, guanylate cyclase is activated in smooth muscle which leads to the formation of cyclic guanosine 3', 5'-monophosphate (cGMP), a transduction mechanism for a number of stimuli in addition to those  
25 leading to muscle relaxation and vasodilatation.

In a preferred embodiment of the invention, the medicament is suitable for oral administration. In this case, the medicament may be a tablet, pill, capsule or powder. In a  
30 particularly preferred embodiment, the medicament, especially a tablet, is coated with an enteric coating which is selected so that it dissolves at a desired location in the gastrointestinal tract, such as at the terminal ileum. A number of such enteric coatings are known.

Many of these take the form of pH sensitive polymers. The polymer is coated onto the surface of the medicament and the active substance is released only after the coating has dissolved. Enteric coatings that may be used in conjunction with the medicaments of the invention include, for example, cellulose acetate 1,2 benzedicarboxylate, hexadecan-1-ol, cellulose ethyl ether, liquid glucpse, cellulose 2-hydroxyethylether, cellulose 2-hydroxypropylether, cellulose 2-hydroxypropyl methyl ether, cellulose hydrogen 1,2 benzene dicarboxylate 2-hydroxypropylmethyl ether, maltodextrin, cellulose methylether, polymethacrylates, shellac, confectioner's sugar, titanium oxide, carnauba wax, microcrystalline wax, zein, gelatin, polyvinyl ethanol and cellulose carboxymethyl ether sodium salt. It is also possible to blend the L-arginine, derivative or salt with a polymer before coating the medicament or to use an appropriate polymer matrix. Microspheres, for example, having controlled release coatings may be used. Using such systems the active ingredient is released at the desired location and sustained or controlled release of the active ingredient at the site can be achieved. Drug delivery systems that are colon specific may also be used in conjunction with the present invention in order to effect release of the active substance in the colon. Drug delivery systems are known that effect selective targeting to the ascending, transverse or descending sections of the colon. For example, coatings are known that are degraded by colonic bacteria. Many further means and formulations for achieving controlled, sustained or targeted release are known.

---

In summary, a desired sustained, controlled and/or targeted release may be achieved, for example, by use of an enteric coating; by use of a sustained release or controlled

release formulation, for example, coated microspheres or an appropriate polymer or polymer matrix; or by a formulation or a drug delivery system that is targeted or specific for a particular region of the gastrointestinal tract. Such means  
5 may be used singly or in any desired combination.

Accordingly, a sustained and/or controlled release medicament may comprise more than one means for achieving the desired effect, for example, a medicament may comprise microspheres or a core comprising a polymer to achieve sustained and/or  
10 controlled release with an enteric coating to achieve targeted release.

The amount of the L-arginine, derivative thereof or pharmaceutically acceptable salt thereof administered is  
15 preferably such that an effective quantity of the active substance reaches the rectum, anus or colon. In a preferred embodiment, from 0.1 mg to 5 g of L-arginine reach the rectum, anus or colon, more preferably from 10 mg to 1 g reach the rectum, anus or colon, still more preferably 50 mg  
20 to 800 mg reach the rectum, anus or colon. Preferably, the requisite amount of the active substance reaches the descending colon or the rectum.

In a further embodiment, the pharmaceutically acceptable  
25 carrier is a solution. In a further embodiment, the pharmaceutically acceptable carrier is an enema solution. It is preferably not a solution of L-arginine in saline for oral administration.

30 The invention further provides the use of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof in conjunction with one or more further laxative  
medicaments. In a preferred embodiment, a further laxative medicament is a bulk-forming laxative, an osmotic laxative, a

stimulatory agent or a softening agent. The further laxative and the L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof may be administered simultaneously, separately or sequentially. When used in  
5 conjunction with a bulk laxative comprising a cellulose ether, especially a water-soluble, non-ionic cellulose ether, it is preferable that the L-arginine active ingredient is not an L-arginine derivative that is a surfactant, particularly not an acyl arginine ester that is a surfactant, for example  
10 not N-myristoyl-L-arginine methyl ester hydrochloride.

A number of methods of surgery, therapy and diagnosis require good access to the gastrointestinal tract, so clearing the gastrointestinal tract, in particular the lower parts of the  
15 gastrointestinal tract, is carried out using, for example, polyethylene glycol. However, effective clearance is difficult to achieve.

As indicated above, the invention includes the use of L-  
20 arginine, a derivative thereof or a pharmaceutically acceptable salt thereof to clear the colon and/or rectum by administering a composition comprising the L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof to the gastrointestinal tract, especially to an area  
25 thereof, for example, to the rectum or the colon. The composition comprising L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof may be used in conjunction with a further active ingredient with a complimentary mode of action, for example a rectal product  
30 comprising a softening agent or a bulk forming laxative given orally, as described above. In a preferred embodiment, the ~~pharmaceutically acceptable carrier is a cream, an anal~~  
suppository base, a hydrogel, hydroxy methyl cellulose; or a water-soluble jelly for example, a water based gel, for

example, as available from Johnson and Johnson under the name "K-Y Jelly". Alternatively, the pharmaceutically acceptable carrier may be an enema solution. In a particularly preferred embodiment, the medicament is in a form suitable  
5 for oral ingestion, as described above and also as described below in relation to treatment of constipation.

As indicated above, such a regime may be used for at least partially clearing the colon prior to a diagnostic procedure  
10 or prior to surgery carried out on the colon or rectum, for example, for example colonoscopy or sigmoidoscopy, or carried out on other structures elsewhere in the abdomen.

The present invention is concerned with treatment of  
15 constipation. As indicated above, constipation may be acute, chronic or refractory and may be endogenous or exogenous. Opiate-induced constipation is particularly refractory and difficult to treat and causes considerable discontent, particularly for those on long-term opiate treatment for  
20 pain, for example, cancer patients.

According to the present invention constipation, including opiate-induced constipation, may be treated using L-arginine, a derivative thereof or a salt thereof, administered either  
25 topically via the rectum using one of the topical medicaments described above or, preferably, administered orally using a medicament that has, preferably, a sustained, controlled and/or targeted release formulation. As pointed out above, sustained and/or controlled release formulations are known in  
30 the art as are means for achieving targeted release. A desired sustained, controlled and/or targeted release may be achieved, for example, by use of an enteric coating; by use of a sustained release or controlled release formulation, for example, coated microspheres or an appropriate polymer or

polymer matrix; or by a formulation or a drug delivery system that is targeted or specific for a particular region of the gastrointestinal tract. Such means may be used singly or in any desired combination. Accordingly, a sustained and/or  
5 controlled release medicament may comprise more than one means for achieving the desired effect, for example, a medicament may comprise microspheres or a core comprising a polymer to achieve sustained and/or controlled release with an enteric coating to achieve targeted release.

10 For the treatment of constipation, including opiate-induced constipation, the L-arginine, derivative or salt thereof may preferably be released after the pyloric sphincter, as example, as described above. Enteric coatings suitable for  
15 release after passage of the medicament through the stomach are known. Release may occur, for example, in the duodenum, ileum or colon. Coatings are known, for example, which dissolve in the terminal ileum, releasing active substance in the colon. It may be preferable to have slow controlled  
20 release of the active substance as the medicament passes through the gastrointestinal tract, for example, through area thereof, for example as described above. As indicated above, a suitable sustained/controlled release formulation may be coated with an enteric coating, for example to achieve  
25 sustained and controlled release along the gastrointestinal tract, for example, starting at the duodenum, or starting at the colon. For release in the colon, a colon-specific drug delivery system may be used, optionally in combination with a sustained/controlled release formulation.

30 An enteric coating may be selected so that it dissolves at a desired location in the gastrointestinal tract, for example, at the duodenum or terminal ileum. A number of such enteric coatings are known. Many of these take the form of pH



sensitive polymers. The polymer is coated onto the surface of the medicament and the active substance is released only after the coating has dissolved. Enteric coatings that may be used in conjunction with the medicaments for the treatment of constipation including opiate-induced constipation include, for example, cellulose acetate 1,2 benzedicarboxylate, hexadecan-1-ol; cellulose ethyl ether, liquid glucose, cellulose 2-hydroxyethylether, cellulose 2-hydroxypropylether, cellulose 2-hydroxypropyl methyl ether, cellulose hydrogen 1,2 benzene dicarboxylate 2-hydroxypropylmethyl ether, maltodextrin, cellulose methylether, polymethacrylates, shellac, confectioner's sugar, titanium oxide, carnauba wax, microcrystalline wax, zein, gelatin, polyvinyl ethanol and cellulose carboxymethyl ether sodium salt.

As indicated above, sustained and/or controlled release may be achieved by blending the L-arginine, derivative or salt with a polymer or a polymer matrix. Microspheres may be used for sustained and/or controlled release. Such microspheres may have differentially soluble coatings, for example, the same coating at different thicknesses or coatings soluble under different conditions, for example at different pH values as in the case of enteric coatings. If an enteric coating is also used, the active ingredient is released at the desired location and sustained or controlled release of the active ingredient in downstream regions is also achieved.

Drug delivery systems that are colon specific may also be used in order to effect release of the active substance in the colon. Drug delivery systems are known that effect selective targeting to the ascending, transverse or descending sections of the colon. For example, coatings are known that are degraded by colonic bacteria. Again, such a

coating may be used in conjunction with a sustained and/or controlled release formulation.

Medicaments for use as a laxative are, for example, as  
5 described above for treatment of constipation.

The invention further provides a topical preparation for use as a laxative, for the treatment of constipation, or for clearing the colon and/or rectum, said preparation  
10 comprising:

- a therapeutically effective amount of L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof at a concentration of more than 100 mg L-arginine/ml;
- 15 - a pharmaceutically acceptable carrier, said carrier comprising a vehicle for topical administration of the L-arginine to an area of the gastrointestinal tract, said pharmaceutically acceptable carrier selected from a water soluble jelly, a hydrogel, an  
20 anal suppository, an enema solution and a solution.

The invention further provides an article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said  
25 pharmaceutical agent comprises L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier suitable for topical application, and wherein the packaging material comprises a label which indicates that the pharmaceutical agent can be  
30 used as a laxative, for treating constipation or for clearing the colon and/or rectum. The article of manufacture may further comprise an applicator.

The present invention provides a medicament comprising L-arginine, a derivative thereof or a salt thereof, in admixture with a pharmaceutically acceptable carrier, the medicament comprising one or more of the following means: a  
5 coating that dissolves at a desired location in the gastrointestinal tract; a sustained release formulation; a controlled release formulation and a drug delivery system. The means or combination of means are such that the L-arginine is released at the desired area of the  
10 gastrointestinal tract in a sustained and/or controlled manner.

The present invention provides a medicament comprising L-arginine, a derivative thereof or a salt thereof, in  
15 admixture with a pharmaceutically acceptable carrier, the medicament comprising an enteric coating that dissolves at a desired location in the gastrointestinal tract, especially in the terminal ileum.

20 The present invention provides a medicament comprising L-arginine, a derivative thereof or a salt thereof, in admixture with a pharmaceutically acceptable carrier, the medicament having a sustained or controlled release formulation.

25 The present invention further provides a medicament comprising L-arginine, a derivative thereof or a salt thereof, in admixture with a pharmaceutically acceptable carrier comprising a colon-specific drug delivery system.

30 The amount of the L-arginine, derivative thereof or salt thereof to be administered may be from 0.001 mg, for example, from 0.1 mg, for example, from 0.5 mg, for example, from 4 mg, for example, from 10 mg, for example, from 50 mg,

calculated as L-arginine. The amount administered may be up to 8000 mg, for example, up to 7000 mg, for example, up to 5000 mg, for example, up to 4000 mg for example, up to 1000 mg, for example up to 800 mg, calculated as L-arginine.

5 Preferred ranges may be selected from any of the lower values set out above in combination with any of the upper values. Particularly preferred ranges for particular applications are given above.

10 A nutritional supplement comprising a Serona repens extract, at least one mineral, at least one vitamin and, optionally L-arginine is described in GB 2,323,531. Medicaments for use as laxatives according to the present invention preferably do not comprise the following combination of substances: Serona  
15 repens extract, at least one mineral, and at least one vitamin.

The following non-limiting Examples illustrate the invention.

20 EXAMPLES:

1. Application of L-arginine to patients with anal fissures.

28 patients suffering from anal fissures were recruited.  
25 Each patient was treated with a 4 ml dose of L-arginine gel. The L-arginine in water based jelly (here "K-Y Jelly" as supplied by Johnson and Johnson) was made up to contain 100 mg L-arginine per ml of gel. The L-arginine gel was applied into the anal canal with use of  
30 an applicator. In each patient, once the gel had diffused, rapid and uncontrollable defecation occurred.  
No other side effects, (e.g. headaches) were noted.

2. Application of L-arginine to the rectum in healthy volunteers.

Six healthy volunteers, (3 male, 3 female, median age 46, range 23-51 years) were recruited. One of the subjects was known to have a history of migraine.

Each patient was treated with a 1 ml dose of L-arginine gel, the gel having been made up to contain 400 mg of L-arginine per ml of hydroxymethyl cellulose. The 1 ml of L-arginine gel was applied from a 2.5 ml syringe directly into the rectum by ejection of 2 ml of gel from a 2.5 ml syringe with an attached canula with a known dead-volume of 1 ml. The canula was inserted 6 cm into the anus so that the gel was brought into contact with the rectum.

All six of the subjects experienced a severe urge to defecate, which was accompanied by slimy diarrhoea in three of them. None of the subjects experienced any headaches.

CLAIMS

1. Use of L-arginine, or a derivative thereof, or a  
pharmaceutically acceptable salt thereof for the manufacture  
5 of a medicament for the treatment of constipation.

2. Use of L-arginine, a derivative thereof or a  
pharmaceutically acceptable salt thereof for the manufacture  
of a medicament for use as a laxative.

10

3. Use of L-arginine, a derivative thereof, or a  
pharmaceutically acceptable salt thereof for the manufacture  
of a medicament for clearing the rectum and/or the colon of a  
mammal.

15

4. Use as claimed in claim 3, wherein the colon and/or  
rectum are cleared prior to carrying out a diagnostic,  
therapeutic or surgical procedure on the colon, rectum or  
anus or elsewhere in the abdomen.

20

5. Use as claimed in claim 4 wherein the diagnostic or  
surgical procedure is a colonoscopy or sigmoidoscopy.

6. Use as claimed in any one of claims 1 to 5 wherein the  
25 L-arginine or derivative thereof is L-arginine.

7. Use as claimed in any one of claims 1 to 6 wherein the  
pharmaceutically acceptable salt of L-arginine is L-arginine  
hydrochloride.

30

8. Use as claimed in any one of claims 1 to 7 wherein the  
~~medicament is suitable for topical application to an area of~~  
the gastrointestinal tract.

9. Use as claimed in any one of claims 1 to 8 wherein the medicament is suitable for rectal administration.

10. Use as claimed in claim 9 wherein the medicament  
5 comprises a pharmaceutically acceptable carrier which is a water-soluble jelly, a hydrogel or hydroxy methyl cellulose.

11. Use as claimed in claim 9 wherein the medicament  
comprises a pharmaceutically acceptable carrier which is an  
10 anal suppository base, or a cream.

12. Use as claimed in claim 9 wherein the medicament  
comprises a pharmaceutically acceptable carrier that is an  
enema solution.

15  
13. Use as claimed in any one of claims 1 to 12 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of from 0.1 mg to 800 mg per ml, calculated as L-arginine.

20  
14. Use as claimed in any one of claims 1 to 12 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of from 10 mg to 700 mg per ml, calculated as L-arginine.

25  
15. Use as claimed in any one of claims 1 to 12 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of from 50 mg to 500 mg per ml, calculated as L-arginine.

30  
16. Use as claimed in any one of claims 1 to 12 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of 400 mg per ml, calculated as L-arginine.

17. Use as claimed in any one of claims 13 to 16, wherein from 0.1 to 800 mg of the medicament are administered.

5 18. Use as claimed in any one of claims 1 to 7 wherein the medicament is suitable for oral administration.

19. Use as claimed in claim 18 wherein the medicament is a tablet, a capsule or a powder.

10

20. Use as claimed in claim 18 wherein the medicament comprises one or more means selected from an enteric coating that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release  
15 formulation; a targeted drug delivery system.

21. Use as claimed in claim 20 wherein the means are such that the L-arginine, derivative thereof, or pharmaceutically acceptable salt thereof is applied to a specific area of the  
20 gastrointestinal tract.

22. Use as claimed in claim 20 wherein the area of the gastrointestinal tract is the gastrointestinal tract beyond the ileum.

25

23. Use as claimed in claim 20 wherein the area of the gastrointestinal tract is the colon and beyond.

24. Use as claimed in claim 20 wherein the area of the  
30 gastrointestinal tract is the rectum or anal canal.

25. Use as claimed in any one of claims 1 to 24 wherein the medicament further comprises a bulk-forming laxative, an



osmotic laxative, a stimulatory laxative or a softening agent for simultaneous, separate or sequential administration.

26. Use as claimed in any one of claims 1 to 25 wherein from 5 0.1 mg to 5 g of L-arginine reach the rectum, anus or colon.

27. Use as claimed in any one of claims 1 to 25, wherein from 10 mg to 1 g of L-arginine reach the rectum, anus or colon.

10

28. Use as claimed in any one of claims 1 to 25, wherein from 50 mg to 800 mg of L-arginine reach the rectum, anus or colon.

15 29. Use of L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament suitable for oral administration for clearing the rectum and/or the colon of a mammal.

20 30. A topical preparation for use as a laxative, for the treatment of constipation, or for emptying the colon and/or rectum, said preparation comprising:

- a therapeutically effective amount of L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof at a concentration of more than 100 mg L-arginine/ml;
- a pharmaceutically acceptable carrier, said carrier comprising a vehicle for topical administration of the L-arginine to an area of the gastrointestinal tract, said pharmaceutically acceptable carrier selected from a water soluble jelly, an anal  
30  
suppository, an enema solution and a solution.

31. A method for the treatment of constipation in a mammal comprising administering to an area of the gastrointestinal tract of the mammal a medicament comprising L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier.

32. A method for promoting or assisting defecation in a mammal comprising administering to an area of the gastrointestinal tract of the mammal a medicament comprising L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier.

33. A method for clearing the colon and/or rectum of a mammal, comprising administering to an area of the gastrointestinal tract of the mammal a medicament comprising L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier.

34. A method as claimed in claim 33, wherein the colon and/or rectum are cleared prior to carrying out a diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen.

35. A method as claimed in claim 34 wherein the diagnostic or surgical procedure is a colonoscopy or sigmoidoscopy.

36. A method as claimed in any one of claims 31 to 35 wherein the L-arginine or derivative thereof is L-arginine.

37. A method as claimed in any one of claims 30 to 36 wherein the pharmaceutically acceptable salt of L-arginine is L-arginine hydrochloride.

5 38. A method as claimed in any one of claims 30 to 37 wherein the medicament is suitable for topical application to an area of the gastrointestinal tract.

39. A method as claimed in any one of claims 30 to 38  
10 wherein the medicament is suitable for rectal administration.

40. A method as claimed in claim 39 wherein the medicament comprises a pharmaceutically acceptable carrier which is a water-soluble jelly, a hydrogel, or hydroxy methyl cellulose.  
15

41. A method as claimed in claim 39 wherein the medicament comprises a pharmaceutically acceptable carrier which is an anal suppository base or a cream.

20 42. A method as claimed in claim 39 wherein the medicament comprises an enema solution.

43. A method as claimed in any one of claims 31 to 42 in which the L-arginine, derivative thereof, or a  
25 pharmaceutically acceptable salt thereof has a concentration in the medicament of from 0.1 mg to 800 mg per ml, calculated on the basis of L-arginine.

44. A method as claimed in any one of claims 31 to 42 in  
30 which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of from 10 mg to 700 mg per ml, calculated on the basis of L-arginine.

45. A method as claimed in any one of claims 31 to 42 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration in the medicament of from 50 mg to 500 mg per ml, calculated  
5 on the basis of L-arginine.

46. A method as claimed in any one of claims 31 to 42 in which the L-arginine, derivative thereof, or a pharmaceutically acceptable salt thereof has a concentration  
10 in the medicament of 400 mg per ml, calculated on the basis of L-arginine.

47. A method as claimed in any one of claims 43 to 46, wherein from 0.1 to 800 mg of the medicament are  
15 administered.

48. A method as claimed in any one of claims 31 to 37 wherein the medicament is suitable for oral administration.

20 49. A method as claimed in claim 48 wherein the medicament is a tablet, a capsule or a powder.

50. A method as claimed in claim 48 wherein the medicament comprises one or more means selected from an enteric coating  
25 that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system.

51. A method as claimed in claim 50 wherein the means are  
30 such that the L-arginine, derivative thereof, or pharmaceutically acceptable salt thereof is applied to a specific area of the gastrointestinal tract.

52. A method, as claimed in claim 50 wherein the area of the gastrointestinal tract is the gastrointestinal tract beyond the ileum.

5 53. A method as claimed in claim 50 wherein the area of the gastrointestinal tract is the colon and beyond.

54. A method as claimed in claim 50 wherein the area of the  
10 gastrointestinal tract is the rectum or anal canal.

55. A method as claimed in any one of claims 31 to 54 wherein the medicament further comprises a bulk-forming laxative, an osmotic laxative, a stimulatory laxative or a  
15 softening agent for simultaneous, separate or sequential administration.

56. A method as claimed in any one of claims 31 to 55, wherein from 0.1 mg to 5 g of L-arginine reach the rectum, ~~or~~  
20 anus or colon.

57. A method as claimed in any one of claims 31 to 55, wherein from 10 mg to 1 g of L-arginine reach the rectum, anus or colon.

25 58. A method as claimed in any one of claims 31 to 55, wherein from 50 mg to 800 mg of L-arginine reach the rectum, anus or colon.

30 59. A method for clearing the rectum and/or the colon of a mammal, comprising administering to an area of the gastrointestinal tract of the mammal a medicament comprising L-arginine, a derivative thereof, or a pharmaceutically acceptable salt thereof in admixture or conjunction with a

pharmaceutically acceptable carrier in a form suitable for oral administration.

60. An article of manufacture comprising packaging material  
5 and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier suitable for topical application, and wherein the  
10 packaging material comprises a label which indicates that the pharmaceutical agent can be used for treating constipation.

61. The article of manufacture as claimed in claim 60  
15 wherein the article further comprises an applicator.

62. A medicament comprising L-arginine, a derivative thereof or a salt thereof, in admixture with a pharmaceutically acceptable carrier, the medicament comprising one or more means selected from an enteric coating that dissolves at a  
20 desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number  
**WO 01/28538 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/198**,  
A61P 1/10

(74) Agents: ADAMS, Nicola et al.; Abel & Imray, 20 Red  
Lion Street, London WC1R 4PQ (GB).

(21) International Application Number: PCT/GB00/04017

(22) International Filing Date: 18 October 2000 (18.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9924636.5 18 October 1999 (18.10.1999) GB

(71) Applicants (for all designated States except US):  
**NORGINE RESEARCH LIMITED** [GB/GB]; Mount  
Vernon Hospital, Rickmansworth Road, Northwood, Mid-  
dlesex HA6 2RN (GB). **PRESIDENT AND FELLOWS  
OF HARVARD COLLEGE** [US/US]; University Place,  
124 Mt. Auburn Street, Cambridge, MA 02138 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARRAS, Norman**  
[GB/GB]; Norgine Research Limited, Mount Vernon Hos-  
pital, Rickmansworth Road, Northwood, Middlesex HA6  
2RN (GB). **HECHTMAN, Herbert, B.** [US/US]; 3 Gle-  
noe Road, Chestnut Hill, MA 02467 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
13 June 2002

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: LAXATIVE PREPARATION CONTAINING L-ARGININE

(57) Abstract: The invention relates to L-arginine, a derivative thereof or a pharmaceutically acceptable salt thereof for use as a laxative, for treatment of constipation and for clearing the rectum and/or the colon of a mammal. Composition suitable for topical administration to an area of the gastrointestinal tract are provided. Orally administered preparations comprising for example an enteric coating that dissolves at a desired location in the gastrointestinal tract; a controlled release formulation; a sustained release formulation; a targeted drug delivery system; or a combination thereof are also provided.

WO 01/28538 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04017

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/198 A61P1/10

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, EPO-Internal, WPI Data, PAJ, BIOSIS, SCISEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	KARAN, R. S. ET AL: "Effect of acute and chronic administration of L-arginine on morphine-induced inhibition of gastrointestinal motility" INDIAN J. PHYSIOL. PHARMACOL. (2000), 44(3), 345-349 , XP001012477 page 347, column 2, paragraph 1 - paragraph 2; figure 2 page 348, column 1, paragraph 1	1-29, 31-59
P, X	STORR M. ET AL: "'Motility-modifying drugs! MOTILITATSMODIFIZIERENDE PHARMAKA." INTERNIST, (2000) 41/12 (1318-1330). , XP001012467 page 131, column 1, paragraph 4 -column 2, paragraph 1	30,60-62

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

18 July 2001

Date of mailing of the international search report

14/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Bonzano, C



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04017

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CALIGNANO, A. ET AL: "Endogenous nitric oxide modulates morphine-induced constipation" BIOCHEM. BIOPHYS. RES. COMMUN. (1991), 181(2), 889-93 , XP001010273 page 892, paragraph 3 ---	1-29, 31-59
X	IZZO, ANGELO-A. ET AL: "NG-Nitro-L-arginine methyl ester modulates intestinal secretion and motility produced by carbachol" EUR. J. PHARMACOL. (1994), 271(1), 31-5 , XP001012470 page 34, column 1, paragraph 2 ---	1-29, 31-59
X	MASCOLO, NICOLA ET AL: "Nitric oxide and castor oil-induced diarrhea" J. PHARMACOL. EXP. THER. (1994), 268(1), 291-5 , XP001012471 page 293, column 1, paragraph 3 ---	1-29, 31-59
X	US 5 693 312 A (VIGANO LUIGI ET AL) 2 December 1997 (1997-12-02) examples 1-8 -----	30,60-62

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1-5, 8-35, 38-62 relate to a compound defined (inter alia) by reference to the following parameter: arginine derivative.

The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameter the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the parts relating to the use of L-arginine or a pharmaceutical salt thereof.

Claims searched completely: 6, 7, 36, 37.

Claims searched incompletely: 1-5, 8-35, 38-62.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

B


# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5693312 A	02-12-1997	IT 1272149 B	11-06-1997
		BE 1006718 A	22-11-1994
		CA 2120048 A	27-09-1994
		CH 686403 A	29-03-1996
		DE 4410470 A	29-09-1994
		ES 2109131 A	01-01-1998
		FR 2703249 A	07-10-1994
		GB 2276545 A, B	05-10-1994
		JP 6321777 A	22-11-1994
		NL 9400481 A	17-10-1994
		SE 9401005 A	27-09-1994



.

.